Moreover, patients in the “grey-zone”, defined as those with no cirrhosis, persistently normal ALT levels, and moderate levels of serum HBV DNA (between 4 log10 IU/mL and 8 log10 IU/mL), have been considered to be at a significantly higher risk of developing HCC if left untreated compared with patients in the gray zone treated with anti-HBV drugs [2,20]. This evidence concerns the gene GPT and hepatocellular carcinoma.